Though still trailing software in total investment,
biotechnology companies saw bigger gains.
Not exact matches
Silicon Alley is still filled with traditional tech
companies (Fintech, AdTech, etc.), but now we're
seeing Brooklyn attract more UrbanTech and CreativeTech
companies, FoodTech and
Biotechnology popping up in Queens and social good enterprises setting up in Harlem and the Bronx.
And as politicians suggest plans to rectify an imperfect system, many health care
companies feel the heat, particularly
biotechnology companies, which then
see weakened stock prices.
In contrast, let's look at the
biotechnology company Biogen Inc. (BIIB) which trades at a very high price per share of $ 257.85 per share, which is roughly 100 times higher than we
saw with Yamana Gold Inc. above.
If
Biotechnology Value Fund is able to cause the
company to quickly distribute the
company's remaining cash to stockholders, purchasers at these levels should
see a good return on investment.
While it's frightening to
see AVGN hemorrhaging cash,
Biotechnology Value Fund is awake to the opportunity to salvage what remains of the
company's value.
You're a
biotechnology Company that unfortunately is
seeing hard times.